

1. DATE ISSUED MM/DD/YYYY 07/23/2020		1a. SUPERSEDES AWARD NOTICE dated except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	
2. CFDA NO. 93.940 - HIV Prevention Activities_Health Department Based			
3. ASSISTANCE TYPE Cooperative Agreement			
4. GRANT NO. 1 NU62PS924625-01-00 Formerly		5. TYPE OF AWARD Other	
4a. FAIN NU62PS924625		5a. ACTION TYPE New	
6. PROJECT PERIOD MM/DD/YYYY From 08/01/2020		Through 07/31/2025	
7. BUDGET PERIOD MM/DD/YYYY From 08/01/2020		Through 07/31/2021	
8. TITLE OF PROJECT (OR PROGRAM) PS20-2010: Integrated HIV Programs for Health Departments to Support Ending the HIV Epidemic in the United States			

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention**

2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD
AUTHORIZATION (Legislation/Regulations)
PHS ACT, SECT. 318 (42U.S.C. SEC 247C)

9a. GRANTEE NAME AND ADDRESS HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF 920 WILDWOOD DR Missouri Department of Health and Senior Services JEFFERSON CITY, MO 65109-5796		9b. GRANTEE PROJECT DIRECTOR Ms. Christine Smith 920 WILDWOOD DR Community and Public Health JEFFERSON CITY, MO 65109-5796 Phone: 573-751-6439	
10a. GRANTEE AUTHORIZING OFFICIAL Ms. Marcia A Mahaney 920 Wildwood Drive Jefferson City, MO 65109-5796 Phone: 573-751-6014		10b. FEDERAL PROJECT OFFICER Mary Allen 1600 Clifton Rd Atlanta, GA 30333 Phone: 404-639-5200	

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)		12. AWARD COMPUTATION																	
I Financial Assistance from the Federal Awarding Agency Only		a. Amount of Federal Financial Assistance (from item 11m) 2,969,930.00																	
II Total project costs including grant funds and all other financial participation <input type="checkbox"/> I		b. Less Unobligated Balance From Prior Budget Periods 0.00																	
a. Salaries and WageS 172,087.00		c. Less Cumulative Prior Award(s) This Budget Period 0.00																	
b. Fringe Benefits 52,262.00		d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 2,969,930.00																	
c. Total Personnel Costs 224,349.00		13. Total Federal Funds Awarded to Date for Project Period 2,969,930.00																	
d. Equipment 0.00		14. RECOMMENDED FUTURE SUPPORT (Subject to the availability of funds and satisfactory progress of the project):																	
e. Supplies 184,742.00		<table border="1"> <thead> <tr> <th>YEAR</th> <th>TOTAL DIRECT COSTS</th> <th>YEAR</th> <th>TOTAL DIRECT COSTS</th> </tr> </thead> <tbody> <tr> <td>a. 2</td> <td></td> <td>d. 5</td> <td></td> </tr> <tr> <td>b. 3</td> <td></td> <td>e. 6</td> <td></td> </tr> <tr> <td>c. 4</td> <td></td> <td>f. 7</td> <td></td> </tr> </tbody> </table>		YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS	a. 2		d. 5		b. 3		e. 6		c. 4		f. 7	
YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS																
a. 2		d. 5																	
b. 3		e. 6																	
c. 4		f. 7																	
f. Travel 0.00		15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:																	
g. Construction 0.00		a. DEDUCTION																	
h. Other 226,857.00		b. ADDITIONAL COSTS																	
i. Contractual 2,293,073.00		c. MATCHING																	
j. TOTAL DIRECT COSTS → 2,929,021.00		d. OTHER RESEARCH (Add / Deduct Option)																	
k. INDIRECT COSTS 40,909.00		e. OTHER (See REMARKS)																	
l. TOTAL APPROVED BUDGET 2,969,930.00		16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:																	
m. Federal Share 2,969,930.00		a. The grant program legislation																	
n. Non-Federal Share 0.00		b. The grant program regulations.																	
		c. This award notice including terms and conditions, if any, noted below under REMARKS.																	
		d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.																	
		In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.																	

REMARKS (Other Terms and Conditions Attached - Yes No)
New Award: Financial Assistance in the amount of \$2,969,930.00

GRANTS MANAGEMENT OFFICIAL:
Portia Brewer, Grants Management Officer
2939 Flowers Road
TV-2
Atlanta, GA 30341
Phone: 770-488-3185

17.OBJ CLASS 41.51	18a. VENDOR CODE	18b. EIN	19. DUNS 878092600	20. CONG. DIST. 03
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
21. a. 0-9390C1K	b. 20NU62PS924625	c. PS	d. \$226,857.00	e. 75-20-0950
22. a. 0-9390EU4	b. 20NU62PS924625	c. PS	d. \$2,293,073.00	e. 75-20-0950
23. a. 0-9390EU5	b. 20NU62PS924625	c. PS	d. \$450,000.00	e. 75-20-0950

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 2	DATE ISSUED 07/23/2020
GRANT NO. 1 NU62PS924625-01-00	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Missouri Department of Health

1 NU62PS924625-01-00

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **PS20-2010**, entitled “**Integrated HIV Programs for Health Departments to Support Ending the HIV Epidemic in the United States**,” and application dated **April 30, 2020**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of **\$2,969,930** is approved for the Year **01** budget period, which is **August 1, 2020** through **July 31, 2021**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

Component Funding:

Component A: **\$2,519,930**

Component C: **\$450,000**

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

Summary Statement Response Requirement: The review comments on the strengths and weaknesses of the proposal are provided as a part of this award. A response to the weaknesses in these statements must be uploaded for approval into GrantSolutions as a “Grant Note” no later than 30 days from the budget period start date. Provide the award number in the subject line. Failure to submit the required information by the due date, **September 1, 2020**, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Budget Revision Requirement: By **September 01, 2020** the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. **Recipients will report use, or intended use, of unobligated funds in Section 12 “Remarks” of the annual Federal Financial Report.** If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient’s authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of

these actions.

Key Personnel: In addition to the Principal Investigator/Project Director identified in this Notice of Award, the application and work plan included individuals considered key personnel. In accordance 45 CFR Part 75.308, the recipient must request prior approval from CDC to change the following individual/position

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC will provide substantial involvement beyond site visits and regular performance and financial monitoring during the project period. Substantial involvement means that the recipient can expect federal programmatic collaboration or participation in carrying out the effort under the award.

1. Collaborate to ensure coordination and implementation of strategies to support the implementation of comprehensive HIV surveillance and prevention activities.
2. Provide guidance and coordination to funded organizations to improve the quality and effectiveness of work plans, evaluation strategies, products and services, and collaborative activities with other organizations.
3. Collaborate to ensure coordination and provide policy and program information for rapid dissemination and implementation.
4. Work with recipients to identify and address capacity building assistance (CBA) and TA needs that are essential to the success of the project.
 - Provide access to training and TA that will strengthen staff capacity relevant to all required strategies and activities of the program.
5. Provide guidance to the recipient and set standards on data collection, use, and submission requirements.
6. Provide technical advice in the development of systems to implement and advance CDC policies, initiatives and programs.
7. Collaborate to ensure coordination and implementation of technical assistance services to state and local health department HIV program staff.
8. Collaborate in assessing progress toward meeting goals/outcomes and in establishing measurement and accountability systems for documenting outcomes, such as increased performance improvements and best or promising practices
9. Provide guidance and coordinate with the recipient to improve the quality and effectiveness of the proposed program. This may include revision of the work plan, evaluation strategy, products and services, among others.
10. Foster and support ongoing opportunities for networking, communication, coordination, and collaboration.
11. Provide consultation in planning, operating, analyzing and evaluating HIV programs, including HIV prevention planning, CDC special initiatives, (e.g., program integration, comprehensive HIV prevention programs, and program evaluation activities.)
12. Monitor recipient program performance using multiple approaches, such as standardized review of performance, recipient feedback and other data reports, to support program development, implementation, evaluation, and improvement.

13. Provide support and facilitate program collaboration with other CDC programs and HHS offices to enhance and improve integration of services.
14. Assist in assessing program operations and in evaluating overall effectiveness of programs.
15. Provide capacity building assistance where identified or as needed to the recipient.
16. Collect and disseminate information, best practices, lessons learned, and evaluation results (e.g., through conferences, guidance, material development, webinars, data sharing publications, other social media, participation in meetings, committees, and working groups related to the cooperative agreement).
17. Provide requirements and expectations for standardized and other data reporting and support monitoring and evaluation activities.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Note: The disposition of program income must have written prior approval from the GMO

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

- Recipients may not use funds for research.
- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body

Indirect costs: Indirect costs are approved based on the negotiated indirect cost rate agreement dated **March 17, 2020**, which calculates indirect costs as follows, a Fixed is approved at a rate of **20.10%** of the base, which includes, direct salaries and wages, including all fringe benefits. The effective dates of this indirect cost rate are from **July 1, 2020** to **June 30, 2021**.

REPORTING REQUIREMENTS

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132 “Performance Progress and Monitoring Report”** **Expiration Date 10/31/2022**. The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services

Rhonda Burton, Grants Management Officer/Specialist
Centers for Disease Control and Prevention
Branch 1-Office of Infectious Disease
2939 Flowers Road MSTV-2
Atlanta, GA 30341
Email: RBurton@cdc.gov

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include “Mandatory Grant Disclosures” in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS).

(45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PROGRAM OR FUNDING GENERAL REQUIREMENTS

Prior Approval: All requests which require prior approval, must bear the signature (or electronic authorization) of the authorized organization representative. Additionally, any requests involving funding issues must include an itemized budget, SF424A, and a narrative justification of the request. An FFR is required for a carryover request.

The following types of requests are examples of actions that require prior approval:

- Lift funding restriction
- Significant redirection of funds (i.e., cumulative changes of 25% of total award)
- Change in scope
- Implement a new activity or enter into a sub-award that is not specified in the approved budget
- Apply for supplemental funds
- Extensions to period of performance

Templates for prior approval requests can be found at:

<https://www.cdc.gov/grants/documents/CDC-non-research-prior-approvals.pdf>

HIV Program Review Panel Requirement: All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Subaccount Title: **20NU62PS924625**

For additional information and/or to obtain your agency point of contact at the PMS, see, <https://pms.psc.gov/find-pms-liaison-accountant.html>

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

Rhonda Burton, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1-Office of Infectious Disease
2939 Flowers Road MSTV-2
Atlanta, GA 30341
Telephone: 770-488-1381
Email: RBurton@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Programmatic Contact:

M. Angie Allen, Project Officer
Centers for Disease Control and Prevention
Division of STD Prevention
8 Corporate Square Blvd room 3028
Atlanta, GA 30329
Telephone: 404-639-8054
Email: idj8@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMO Contact:

Portia Brewer, Grants Management Officer
Centers for Disease Control and Prevention
Branch 1 Office of Infectious Disease
2939 Flowers Road MS TV-2
Atlanta, GA 30341
Telephone: 440-488-3185
Email: PBrewer@cdc.gov